StockData
Agios Pharmaceuticals, Inc. logo

Agios Pharmaceuticals, Inc. (AGIO) stock

AGIONasdaqPharmaceutical PreparationsFiscal year ends December 31
Financials through Q2 FY2026, quarter ended Jun 30, 2026Last filing: 10-Q on Nov 5, 2026Score 12/308% above fair value
$29.89−0.26 (-0.86%)

Close on Nov 17, 2026Market cap $1.78BP/E –Yield –

Agios Pharmaceuticals price to sales ratio

The price-to-sales ratio is market cap divided by revenue over the trailing twelve months.

Agios Pharmaceuticals's price to sales ratio was 19.9× on Nov 11, 2026, against 38.0× a year earlier. Over the last 5 years it ranged from 18.5× to 241.7×, with a median of 57.0×.

Price to Sales Ratio at the end of each year

PeriodPeriod endValueChange (pts)
2026Nov 11, 202619.9×−15.5
2025Dec 31, 202535.4×−21.6
2024Dec 31, 202457.0×+5.2
2023Dec 29, 202351.8×−103.4
2022Dec 30, 2022155.2×+114.4
2021Dec 31, 202140.8×+25.4
2020Dec 31, 202015.4×−9.6
2019Dec 31, 201925.0×−11.2
2018Dec 31, 201836.2×−13.6
2017Dec 29, 201749.8×+17.0
2016Dec 30, 201632.8×−3.4
2015Dec 31, 201536.1×−31.4
2014Dec 31, 201467.5×+37.9
2013Dec 31, 201329.7×–

More Agios Pharmaceuticals figures

See a number that looks wrong?